NDLI: Acute Rosiglitazone Treatment during Reperfusion after Hyperglycemic Stroke is Neuroprotective Not Vascular Protective

Content Provider	Springer Nature Link
Author	Palomares, Sara Morales Sweet, Julie G. Cipolla, Marilyn J.
Copyright Year	2012
Abstract	Reperfusion therapy for ischemic stroke can cause secondary brain injury, especially under hyperglycemic (HG) conditions. Here, we investigated the effect of acute treatment with rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, prior to postischemic reperfusion, on stroke outcome during HG stroke. Male Wistar rats that were either normoglycemic (NG) or HG by STZ (50 mg/kg; for 5–6 days) underwent middle cerebral artery occlusion (MCAO) for 2 h with 2 h of reperfusion. Animals were treated i.v. with rosiglitazone (1 mg/kg; n = 16), rosiglitazone (1 mg/kg) + the free radical scavenger Tempol (50 mg/kg; n = 10) or vehicle (n = 16) 10 min prior to reperfusion and infarct volume, edema formation, and cerebral blood flow (CBF) were measured. Compared to NG, HG stroke significantly increased infarct volume from 5.2 ± 3.0 % vs. 14.7 ± 3.6 % (p < 0.05). Rosiglitazone prevented the increased infarct volume induced by HG that was only 6.9 ± 2.0 % (p < 0.05 vs. HG) but did not have any effect on edema formation that was increased by 3.0 % in both HG vehicle and rosiglitazone-treated ipsilateral vs. contralateral hemispheres (p < 0.05). Combined treatment of rosiglitazone + Tempol did not significantly change brain water content that remained 2.2 % greater than contralateral (p < 0.05) but reversed the neuroprotective properties of rosiglitazone in HG MCAO animals such that infarct volume was 14.3 ± 4.4 % (p > 0.05 vs. vehicle). The lack of an effect of combined treatment of rosiglitazone + Temple may be due to a decrease in reperfusion CBF that was only 60 % of baseline (p < 0.01) compared to 82 % and 89 % for HG vehicle and rosiglitazone-treated animals (p > 0.05). In conclusion, acute rosiglitazone treatment prior reperfusion was neuroprotective but not vascular protective during HG stroke.
Starting Page	390
Ending Page	396
Page Count	7
File Format	PDF
ISSN	18684483
Journal	Translational Stroke Research
Volume Number	3
Issue Number	3
e-ISSN	1868601X
Language	English
Publisher	Springer-Verlag
Publisher Date	2012-05-15
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Ischemic stroke Hyperglycemia Infarct volume Edema Cerebral blood flow Rosiglitazone Vascular Surgery Cardiology Neurology Neurosurgery Neurosciences
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine Neuroscience Neurology (clinical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective

Effect of Hyperglycemia on Brain Penetrating Arterioles and Cerebral Blood Flow Before and After Ischemia/Reperfusion

Uric Acid Is Protective After Cerebral Ischemia/Reperfusion in Hyperglycemic Mice

Fluid Intake Related to Brain Edema in Acute Middle Cerebral Artery Infarction

Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA

Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype

Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke

Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy

Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion

Acute Rosiglitazone Treatment during Reperfusion after Hyperglycemic Stroke is Neuroprotective Not Vascular Protective

Similar Documents

Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protective

Effect of Hyperglycemia on Brain Penetrating Arterioles and Cerebral Blood Flow Before and After Ischemia/Reperfusion

Uric Acid Is Protective After Cerebral Ischemia/Reperfusion in Hyperglycemic Mice

Fluid Intake Related to Brain Edema in Acute Middle Cerebral Artery Infarction

Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA

Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype

Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke

Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy

Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion

Acute Rosiglitazone Treatment during Reperfusion after Hyperglycemic Stroke is Neuroprotective Not Vascular Protective